På dette tidspunkt var det udvalgets opfattelse, at fordelene ved Mycograb til behandling af invasiv candidiasis ikke opvejer risiciene.
At this point in time, the committee was of the opinion that the benefits of Mycograb in the treatment of invasive candidiasis did not outweigh its risks.